161 related articles for article (PubMed ID: 36924654)
1. Ugi reaction-assisted assembly of covalent PROTACs against glutathione peroxidase 4.
Zhu L; Hu S; Yan X; Zeng Q; Zhang B; Jiang L; Yao SQ; Ge J
Bioorg Chem; 2023 May; 134():106461. PubMed ID: 36924654
[TBL] [Abstract][Full Text] [Related]
2. Design and synthesis of proteolysis-targeting chimeras (PROTACs) as degraders of glutathione peroxidase 4.
Cai M; Ma F; Hu C; Li H; Cao F; Li Y; Dong J; Qin JJ
Bioorg Med Chem; 2023 Jul; 90():117352. PubMed ID: 37257255
[TBL] [Abstract][Full Text] [Related]
3. A potent GPX4 degrader to induce ferroptosis in HT1080 cells.
Song H; Liang J; Guo Y; Liu Y; Sa K; Yan G; Xu W; Xu W; Chen L; Li H
Eur J Med Chem; 2024 Feb; 265():116110. PubMed ID: 38194774
[TBL] [Abstract][Full Text] [Related]
4. Dual degradation mechanism of GPX4 degrader in induction of ferroptosis exerting anti-resistant tumor effect.
Wang C; Zheng C; Wang H; Shui S; Jin H; Liu G; Xu F; Liu Z; Zhang L; Sun D; Xu P
Eur J Med Chem; 2023 Feb; 247():115072. PubMed ID: 36603510
[TBL] [Abstract][Full Text] [Related]
5. Discovery of ML210-Based glutathione peroxidase 4 (GPX4) degrader inducing ferroptosis of human cancer cells.
Wang H; Wang C; Li B; Zheng C; Liu G; Liu Z; Zhang L; Xu P
Eur J Med Chem; 2023 Jun; 254():115343. PubMed ID: 37087895
[TBL] [Abstract][Full Text] [Related]
6. Structure-activity relationship study of RSL3-based GPX4 degraders and its potential noncovalent optimization.
Zheng C; Wang C; Sun D; Wang H; Li B; Liu G; Liu Z; Zhang L; Xu P
Eur J Med Chem; 2023 Jul; 255():115393. PubMed ID: 37098297
[TBL] [Abstract][Full Text] [Related]
7. Design, Synthesis, and Biological Evaluation of Hydrophobic-Tagged Glutathione Peroxidase 4 (GPX4) Degraders.
Li X; Hu M; Zhang Y; Hua H; Sun Y; Xiang Q; Zhu D
Bioorg Chem; 2024 Mar; 144():107115. PubMed ID: 38232684
[TBL] [Abstract][Full Text] [Related]
8. Solid-Phase Synthesis of Cereblon-Recruiting Selective Histone Deacetylase 6 Degraders (HDAC6 PROTACs) with Antileukemic Activity.
Sinatra L; Yang J; Schliehe-Diecks J; Dienstbier N; Vogt M; Gebing P; Bachmann LM; Sönnichsen M; Lenz T; Stühler K; Schöler A; Borkhardt A; Bhatia S; Hansen FK
J Med Chem; 2022 Dec; 65(24):16860-16878. PubMed ID: 36473103
[TBL] [Abstract][Full Text] [Related]
9. Effective degradation of EGFR
Qu X; Liu H; Song X; Sun N; Zhong H; Qiu X; Yang X; Jiang B
Eur J Med Chem; 2021 Jun; 218():113328. PubMed ID: 33773286
[TBL] [Abstract][Full Text] [Related]
10. ZX703: A Small-Molecule Degrader of GPX4 Inducing Ferroptosis in Human Cancer Cells.
Hu M; Li X; Wang L; Zhang Y; Sun Y; Hua H; Liu H; Cai T; Zhu D; Xiang Q
ACS Med Chem Lett; 2024 Mar; 15(3):406-412. PubMed ID: 38505849
[TBL] [Abstract][Full Text] [Related]
11. A GPX4 non-enzymatic domain and MDM2 targeting peptide PROTAC for acute lymphoid leukemia therapy through ferroptosis induction.
Niu F; Yang R; Feng H; Liu Y; Liu R; Ma B
Biochem Biophys Res Commun; 2023 Dec; 684():149125. PubMed ID: 37897912
[TBL] [Abstract][Full Text] [Related]
12. Discovery of Novel Potent Covalent Glutathione Peroxidase 4 Inhibitors as Highly Selective Ferroptosis Inducers for the Treatment of Triple-Negative Breast Cancer.
Chen T; Leng J; Tan J; Zhao Y; Xie S; Zhao S; Yan X; Zhu L; Luo J; Kong L; Yin Y
J Med Chem; 2023 Jul; 66(14):10036-10059. PubMed ID: 37452764
[TBL] [Abstract][Full Text] [Related]
13. Intracellular Delivery of Glutathione Peroxidase Degrader Induces Ferroptosis In Vivo.
Luo T; Zheng Q; Shao L; Ma T; Mao L; Wang M
Angew Chem Int Ed Engl; 2022 Sep; 61(39):e202206277. PubMed ID: 35924720
[TBL] [Abstract][Full Text] [Related]
14. PROTACs: Current Trends in Protein Degradation by Proteolysis-Targeting Chimeras.
Madan J; Ahuja VK; Dua K; Samajdar S; Ramchandra M; Giri S
BioDrugs; 2022 Sep; 36(5):609-623. PubMed ID: 36098871
[TBL] [Abstract][Full Text] [Related]
15. Targeting GPX4 in human cancer: Implications of ferroptosis induction for tackling cancer resilience.
Lee J; Roh JL
Cancer Lett; 2023 Apr; 559():216119. PubMed ID: 36893895
[TBL] [Abstract][Full Text] [Related]
16. Fluorescence theranostic PROTACs for real-time visualization of ERα degradation.
Wang X; Xin L; Deng X; Dong C; Hu G; Zhou HB
Eur J Med Chem; 2024 Mar; 267():116184. PubMed ID: 38320426
[TBL] [Abstract][Full Text] [Related]
17. Discovery of pomalidomide-based PROTACs for selective degradation of histone deacetylase 8.
Sun Z; Deng B; Yang Z; Mai R; Huang J; Ma Z; Chen T; Chen J
Eur J Med Chem; 2022 Sep; 239():114544. PubMed ID: 35759908
[TBL] [Abstract][Full Text] [Related]
18. Mathematical Model for Covalent Proteolysis Targeting Chimeras: Thermodynamics and Kinetics Underlying Catalytic Efficiency.
Chaudhry C
J Med Chem; 2023 May; 66(9):6239-6250. PubMed ID: 37102218
[TBL] [Abstract][Full Text] [Related]
19. Ketamine suppresses proliferation and induces ferroptosis and apoptosis of breast cancer cells by targeting KAT5/GPX4 axis.
Li H; Liu W; Zhang X; Wu F; Sun D; Wang Z
Biochem Biophys Res Commun; 2021 Dec; 585():111-116. PubMed ID: 34800882
[TBL] [Abstract][Full Text] [Related]
20. One-Pot Synthesis of Cereblon Proteolysis Targeting Chimeras via Photoinduced C(sp
Arndt CM; Bitai J; Brunner J; Opatz T; Martinelli P; Gollner A; Sokol KR; Krumb M
J Med Chem; 2023 Dec; 66(24):16939-16952. PubMed ID: 38096359
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]